Belimumab denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belimumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Belimumab

Belimumab (Benlysta) is a specialty biologic used in systemic lupus erythematosus (SLE) and lupus nephritis. UnitedHealthcare places it on a specialty tier requiring prior authorization (PA) for every new course of therapy and, in many plans, for each annual renewal. A "prior-auth-required" denial most often means either that therapy was initiated before authorization was obtained, that the PA request was submitted with incomplete documentation, or that an authorization expired and was not renewed in time. Importantly, this type of denial is administrative in nature and is highly reversible on appeal when the clinical record is complete.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal appeal and, if that fails, an independent external review through an accredited IRO. The external-review window is generally within four months of the final adverse benefit determination. If your clinical condition is urgent or deteriorating, request expedited review — the plan must respond within 72 hours.

## The Appeal Process

1. Request the denial letter and the specific UnitedHealthcare prior-authorization criteria document for belimumab. 2. Have the prescribing physician resubmit or supplement the PA request with all missing documentation before the formal appeal, if timing allows. 3. File a Level 1 internal appeal, attaching the complete documentation package. 4. If upheld, escalate to Level 2 internal review or external IRO review. 5. For urgent situations, request simultaneous expedited review.

## Documentation to Gather

• Diagnosis confirmation: Rheumatology or nephrology records establishing the FDA-approved indication with relevant clinical detail (disease activity, organ involvement) as documented by the treating specialist.
• Prior treatment history: A chronological list of all previously tried therapies with start/stop dates and documented outcomes or reasons for discontinuation, addressing any step-therapy requirements in the UHC policy.
• Clinical severity: Physician notes quantifying disease activity using the assessment tools referenced in the UHC policy (your doctor can specify which tools apply).
• Medical-necessity letter: A comprehensive letter from the prescriber citing the FDA-approved indication, explaining why belimumab is medically necessary for this patient specifically, and confirming that all UHC clinical criteria are met.
• Prior-auth history: Any previous approvals for this drug for this patient, to support continuity-of-care arguments on renewal denials.

## Criteria-Mapping Structure

Download the UnitedHealthcare Medical/Coverage Policy for belimumab and the FDA-approved prescribing label. Create a point-by-point response:

| UHC PA Criterion | Satisfying Documentation | |---|---| | Confirmed FDA-approved diagnosis | Specialist note + applicable diagnostic criteria per chart | | Failure of / intolerance to required prior therapies | List with dates and documented outcomes | | Disease activity threshold (per UHC policy) | Physician assessment note using the measurement tool cited in policy | | Prescriber specialty requirement (if any) | Prescriber credentials and specialty | | Absence of contraindications per policy | Prescriber attestation |

A structured, criterion-by-criterion response significantly improves overturn rates for PA-required denials.